Comprehensive analysis of PILRΑ’s association with the prognosis, tumor immune infiltration, and immunotherapy in pan-cancer

• Published in: Scientific reports Vol. 13; no. 1; p. 14334
• Main Authors: Li, Qiao, Yang, Zhirong, He, Xiaoyan, Yang, Xin
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 31-08-2023; Nature Publishing Group; Nature Portfolio
• Subjects: 631/114; 631/250; 631/67; 692/4028; 692/53; Biomarkers; Cancer; Cancer immunotherapy; Gene expression; Genomes; Humanities and Social Sciences; Immune response; Immunotherapy; Metastases; multidisciplinary; Prognosis; Science; Science (multidisciplinary); Therapeutic targets; Tumor-infiltrating lymphocytes
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-023-41649-6

Paired immunoglobulin-like type 2 receptor alpha (PILRA) plays a vital role in regulating broad immune responses. However, the roles of PILRA in cancer immunity remain unexplored yet. In the current study, we comprehensively analyzed the oncogenic and immunologic roles of PILRA at a pan-cancer level based on the Cancer Genome Atlas and Gene Expression Omnibus datasets. PILRA was significantly dysregulated and frequently mutated in pan-cancer. Its expression and mutation status significantly impacted patient prognosis in several cancers. Besides, PILRA expression was positively correlated with ESTIMATE scores and the abundances of tumor-infiltrating immune cells. Concurrently, PILRA expression was significantly associated with predictive biomarkers of cancer immunotherapy, and positively correlated with the prognostic outcomes of cancer patients receiving immunotherapy. Mechanistically, enrichment analysis implied that PILRA might be involved in the regulation of immune response and metabolic process. This study uncovered the immunological roles of PILRA in cancers and its potential as a novel biomarker and therapeutic target for cancer immunotherapy.